LIVIVO - Search results -

Search results

Result 1 - 10 of total 43

Search options

Article ; Online: A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation.

Criscuolo, Marianna / Fracchiolla, Nicola / Farina, Francesca / Verga, Luisa / Pagano, Livio / Busca, Alessandro

2023 Volume 16, Issue 12, Page(s) 963–980

Abstract: Introduction: The recent introduction of targeted therapies, including monoclonal antibodies, tyrosine-kinase inhibitors, and immunotherapies has improved the cure rate of hematologic patients. The implication of personalized treatment on primary ... ...

Abstract	Introduction: The recent introduction of targeted therapies, including monoclonal antibodies, tyrosine-kinase inhibitors, and immunotherapies has improved the cure rate of hematologic patients. The implication of personalized treatment on primary antifungal prophylaxis will be discussed. Areas covered: We reviewed the literature for clinical trials reporting the rate of invasive fungal infections during targeted and cellular therapies and stem cell transplant, and the most recent international guidelines for primary antifungal prophylaxis. Expert opinion: As the use of personalized therapies is growing, the risk of invasive fungal infection has emerged in various clinical settings. Therefore, it is possible that the use of mold-active antifungal prophylaxis would spread in the next years and the risk of breakthrough infections would increase. The introduction of new antifungal agents in the clinical armamentarium is expected to reduce clinical unmet needs concerning the management of primary antifungal prophylaxis and improve outcome of patients.
MeSH term(s)	Humans ; Antifungal Agents/therapeutic use ; Hematopoietic Stem Cell Transplantation/adverse effects ; Stem Cell Transplantation ; Invasive Fungal Infections/etiology ; Invasive Fungal Infections/prevention & control ; Invasive Fungal Infections/drug therapy ; Hematology
Chemical Substances	Antifungal Agents
Language	English
Publishing date	2023-12-18
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2516804-6
ISSN	1747-4094 ; 1747-4086
ISSN (online)	1747-4094
ISSN	1747-4086
DOI	10.1080/17474086.2023.2290639
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6943: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences.

Rossini, Bernardo / Cecchi, Nicola / Clemente, Felice / De Paolis, Maria Rosaria / Hohaus, Stefan / Innao, Vanessa / Lucignano, Mariano / Massaiu, Roberto / Palumbo, Giovanna / Rigolin, Gian Matteo / Rossi, Francesca Gaia / Verga, Luisa / Guarini, Attilio

Drugs in context

2024 Volume 13

Abstract: Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently ... ...

Abstract	Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for idiopathic multicentric CD and is recommended as first-line therapy in treatment guidelines. Despite the extensive characterization of siltuximab treatment in clinical trials, available evidence from real-world practice is still scant. This collection of clinical experiences focuses on patients treated with siltuximab therapy, particularly regarding the idiopathic multicentric CD diagnostic work-up, and on treatment administration in patients with complex disease entering differential diagnosis with CD or concomitant diseases. Thus, these data help further characterize and improve the use of siltuximab in real practice in terms of effectiveness and safety of long-term administration as well as consequences of treatment interruption.
Language	English
Publishing date	2024-03-12
Publishing country	England
Document type	Journal Article
ZDB-ID	2719560-0
ISSN	1740-4398 ; 1745-1981
ISSN (online)	1740-4398
ISSN	1745-1981
DOI	10.7573/dic.2023-9-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Safety and Effectiveness of Intensive Treatments Administered Outside the Intensive Care Unit to Hematological Critically Ill Patients: An Intensive Care without Walls Trial.

Vergnano, Beatrice / Signori, Davide / Benini, Annalisa / Calcinati, Serena / Bettini, Francesca / Verga, Luisa / Borin, Lorenza Maria / Cavalca, Fabrizio / Gambacorti-Passerini, Carlo / Bellani, Giacomo / Foti, Giuseppe

Journal of clinical medicine

2023 Volume 12, Issue 19

Abstract: Historically, the admission of hematological patients in the ICU shortly after the start of a critical illness is associated with better survival rates. Early intensive interventions administered by MET could play a role in the management of ... ...

Abstract	Historically, the admission of hematological patients in the ICU shortly after the start of a critical illness is associated with better survival rates. Early intensive interventions administered by MET could play a role in the management of hematological critically ill patients, eventually reducing the ICU admission rate. In this retrospective and monocentric study, we evaluate the safety and effectiveness of intensive treatments administered by the MET in a medical ward frame. The administered interventions were mainly helmet CPAP and pharmacological cardiovascular support. Frequent reassessment by the MET at least every 8 to 12 h was guaranteed. We analyzed data from 133 hematological patients who required MET intervention. In-hospital mortality was 38%; mortality does not increase in patients not immediately transferred to the ICU. Only three patients died without a former admission to the ICU; in these cases, mortality was not related to the acute illness. Moreover, 37% of patients overcame the critical episode in the hematological ward. Higher SOFA and MEWS scores were associated with a worse survival rate, while neutropenia and pharmacological immunosuppression were not. The MET approach seems to be safe and effective. SOFA and MEWS were confirmed to be effective tools for prognostication.
Language	English
Publishing date	2023-09-29
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12196281
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.

Pagani, Chiara / Rusconi, Chiara / Dalla Pria, Alessia / Ravano, Emanuele / Schommers, Philipp / Bastos-Oreiro, Mariana / Verga, Luisa / Gini, Guido / Spina, Michele / Arcaini, Luca / Steffanoni, Sara / Dalu, Davide / Crucitti, Lara / Lorenzi, Luisa / Balzarini, Piera / Cattaneo, Chiara / Bongiovanni, Lucia / Rosenwald, Andreas / Facchetti, Fabio /

Bower, Mark / Ferreri, Andrés J M / Rossi, Giuseppe / Tucci, Alessandra / Re, Alessandro

Blood advances

2024 Volume 8, Issue 4, Page(s) 968–977

Abstract: Abstract: Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) ... ...

Abstract	Abstract: Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the HIV population. Scanty data are available on the prevalence and prognostic impact of MYC rearrangements in HIV-associated LBCL. We conducted a retrospective study to evaluate the clinical effect of MYC rearrangement in HIV-associated LBCL. We evaluated clinical characteristics, treatment received, and outcome of LBCL in patients with HIV with MYC rearrangement (MYC+) and without MYC rearrangement (MYC-). A total of 155 patients with HIV who had received fluorescence in situ hybridization analysis for MYC were enrolled in 11 European centers: 43 with MYC+ and 112 MYC-. Among patients with MYC, 10 had double-/triple-hit lymphomas, and 33 had isolated MYC rearrangement (single-hit lymphoma). Patients with MYC+ had more frequently advanced stage, >2 extranodal site at presentation, and higher proliferative index. There were no significant differences in overall survival and progression-free survival (PFS) between the 2 groups. However, patients with MYC+ received more frequently intensive chemotherapy (iCT) (44%) than (R)CHOP alone (35%) or infusional treatment (DA-EPOCH-R and R-CDE) (19%). Among patients with MYC+, those who received iCT achieved a better outcome than patients who received nonintensive treatment (complete remission, 84% vs 52%; P = .028; 5-year PFS, 66% vs 36%; P = .021). Our retrospective results suggest that HIV-associated LBCL with MYC+ could be considered for an intensive therapeutic approach whenever possible, whereas (R)CHOP seems to give inferior results in this subset of patients in terms of complete remission and PFS.
MeSH term(s)	Humans ; Cyclophosphamide/therapeutic use ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; In Situ Hybridization, Fluorescence ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Proto-Oncogene Proteins c-myc/genetics ; Retrospective Studies ; Rituximab/therapeutic use ; Vincristine/therapeutic use
Chemical Substances	Cyclophosphamide (8N3DW7272P) ; Proto-Oncogene Proteins c-myc ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; MYC protein, human
Language	English
Publishing date	2024-01-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2023010704
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study.

Menna, Pierantonio / Marchesi, Francesco / Cattaneo, Chiara / Candoni, Anna / Delia, Mario / Nadali, Gianpaolo / Vatteroni, Alessandra / Pasciolla, Crescenza / Perrone, Salvatore / Verga, Luisa / Armiento, Daniele / Del Principe, Maria Ilaria / Fracchiolla, Nicola S / Salvatorelli, Emanuela / Lupisella, Santina / Terrenato, Irene / Busca, Alessandro / Minotti, Giorgio / Pagano, Livio

Clinical and translational science

2023 Volume 16, Issue 10, Page(s) 1876–1885

Abstract: Midostaurin is used in combination with chemotherapy to treat patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Chemotherapy-induced neutropenia exposes these patients to a significant risk of invasive fungal infections (IFIs). ... ...

Abstract	Midostaurin is used in combination with chemotherapy to treat patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Chemotherapy-induced neutropenia exposes these patients to a significant risk of invasive fungal infections (IFIs). International guidelines recommend primary antifungal prophylaxis with posaconazole (PCZ) but nested analysis of a phase III trial showed that strong PCZ inhibition of CYP3A4 diminished midostaurin metabolism and increased midostaurin plasma levels; however, midostaurin-related adverse events (AEs) were only moderately exacerbated. We conducted a prospective multicenter real-life study to evaluate (i) how often concerns around PCZ-midostaurin interactions made the hematologist prescribe antifungals other than PCZ, (ii) how remarkably PCZ increased midostaurin plasma levels, and (iii) how significantly PCZ-midostaurin interactions influenced hematologic and safety outcomes of induction therapy. Although the hematologists were blinded to pharmacokinetic findings, as many as 16 of 35 evaluable patients were prescribed antifungal prophylaxis with micafungin, weak CYP3A4 inhibitor, in place of PCZ (p < 0.001 for deviation from guidelines). In the 19 patients managed as per guidelines, PCZ-midostaurin interactions were more remarkable than previously characterized, such that at the end of induction therapy midostaurin minimum plasma concentration (C
MeSH term(s)	Humans ; Antifungal Agents/adverse effects ; Micafungin/therapeutic use ; Prospective Studies ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/diagnosis ; Neutropenia ; fms-Like Tyrosine Kinase 3/genetics
Chemical Substances	midostaurin (ID912S5VON) ; posaconazole (6TK1G07BHZ) ; Antifungal Agents ; Micafungin (R10H71BSWG) ; FLT3 protein, human (EC 2.7.10.1) ; fms-Like Tyrosine Kinase 3 (EC 2.7.10.1)
Language	English
Publishing date	2023-07-28
Publishing country	United States
Document type	Multicenter Study ; Journal Article
ZDB-ID	2433157-0
ISSN	1752-8062 ; 1752-8054
ISSN (online)	1752-8062
ISSN	1752-8054
DOI	10.1111/cts.13595
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas.

Rindone, Giovanni / Aroldi, Andrea / Bossi, Elisa / Verga, Luisa / Zambrotta, Giovanni / Tarantino, Sara / Piazza, Rocco / Mussolin, Lara / Chiarle, Roberto / Gambacorti-Passerini, Carlo

Blood advances

2022 Volume 7, Issue 3, Page(s) 314–316

MeSH term(s)	Humans ; Crizotinib/adverse effects ; Receptor Protein-Tyrosine Kinases ; Anaplastic Lymphoma Kinase ; Lymphoma
Chemical Substances	Crizotinib (53AH36668S) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; Anaplastic Lymphoma Kinase (EC 2.7.10.1)
Language	English
Publishing date	2022-08-01
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2022007538
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The spectrum of the cytopathological features of primary effusion lymphoma and human herpes virus 8-related lymphoproliferative disorders.

Verga, Luisa / Leni, Davide / Cazzaniga, Giorgio / Crosta, Simona / Seminati, Davide / Rossi, Marianna / L'Imperio, Vincenzo / Pagni, Fabio

Cytopathology : official journal of the British Society for Clinical Cytology

2020 Volume 31, Issue 6, Page(s) 541–546

Abstract: Introduction: Human herpes virus 8-related lymphoproliferative disorders are a complex and heterogeneous group of entities and some of them are eminently diagnosed by cytopathology. In a routine laboratory, these lesions account for less than 1% of the ... ...

Abstract	Introduction: Human herpes virus 8-related lymphoproliferative disorders are a complex and heterogeneous group of entities and some of them are eminently diagnosed by cytopathology. In a routine laboratory, these lesions account for less than 1% of the effusion fluids samples. However, they represent up to 30% of all the lymphoma diagnosis from effusion cytological samples and their consideration in the diagnostic flow chart is mandatory, especially in human immunodeficiency virus-positive patients. Methods: A retrospective series of cytological specimens from cavity effusions (n = 605) were analysed. Five human herpes virus 8-related lymphoproliferative processes were recruited. A combination of morphological criteria (enhanced with May-Grünwald Giemsa staining), cell block-based immunocytochemistry and flow cytometry were undertaken for final characterisation. Results: The identification of malignant cells may be difficult. Some specimens are particularly rich, easily leading to suspect a lymphoproliferative process, whereas in other cases, the presence of abundant reactive mesothelial cells, histiocytes, neutrophils, small reactive T and B lymphocytes may obscure the neoplastic process. The biological behaviour may be very heterogeneous and a standardised therapy for these cases is still lacking, although some patients may benefit from antiretroviral therapy in a human immunodeficiency virus setting. Conclusions: The present case series highlights some characteristic findings of these entities to reaffirm useful cytopathological diagnostic criteria, stressing the crucial role of the appropriate technical processing of effusion fluids to obtain the best performances.
MeSH term(s)	Adult ; Aged ; B-Lymphocytes/pathology ; B-Lymphocytes/virology ; Cytodiagnosis ; Female ; Flow Cytometry ; HIV/isolation & purification ; HIV/pathogenicity ; HIV Infections/diagnosis ; HIV Infections/pathology ; HIV Infections/therapy ; HIV Infections/virology ; Herpesvirus 8, Human/isolation & purification ; Herpesvirus 8, Human/pathogenicity ; Humans ; Lymphoma, Primary Effusion/diagnosis ; Lymphoma, Primary Effusion/pathology ; Lymphoma, Primary Effusion/therapy ; Lymphoma, Primary Effusion/virology ; Lymphoproliferative Disorders/diagnosis ; Lymphoproliferative Disorders/pathology ; Lymphoproliferative Disorders/therapy ; Lymphoproliferative Disorders/virology ; Male ; Middle Aged ; T-Lymphocytes/pathology ; T-Lymphocytes/virology
Keywords	covid19
Language	English
Publishing date	2020-05-21
Publishing country	England
Document type	Journal Article
ZDB-ID	1034190-0
ISSN	1365-2303 ; 0956-5507 ; 1350-4037
ISSN (online)	1365-2303
ISSN	0956-5507 ; 1350-4037
DOI	10.1111/cyt.12820
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2926: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).

Bossi, Elisa / Aroldi, Andrea / Borin, Lorenza Maria / Verga, Luisa / Fontana, Diletta / Cocito, Federica / Manghisi, Beatrice / Rindone, Giovanni / Cavalca, Fabrizio / Ripamonti, Alessia / Raggi, Monica / Malandrin, Sergio Maria Ivano / Cavallero, Annalisa / Antolini, Laura / Bonardi, Diego / Piazza, Rocco Giovanni / Gambacorti-Passerini, Carlo

EJHaem

2022

Abstract: Hematological patients at higher risk of severe COVID-19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine trials. In this single-center observational prospective study (NCT05074706), we evaluate immune response ... ...

Abstract	Hematological patients at higher risk of severe COVID-19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine trials. In this single-center observational prospective study (NCT05074706), we evaluate immune response in the hematological patients followed at the Hematological Division of San Gerardo Hospital, Monza (Italy) deemed to be severely immunosuppressed after vaccination with two doses of the BNT162b2 vaccine. Anti-SARS-CoV-2 immunoglobulin G titers above the cutoff value of 33.8 BAU/ml were detected in 303 (80.2%) out of the 378 patients enrolled. Patients with lymphoproliferative disorders had a significant lower probability of immunization (43.2% vs. 88.4%,
Language	English
Publishing date	2022-08-30
Publishing country	United States
Document type	Journal Article
ISSN	2688-6146
ISSN (online)	2688-6146
DOI	10.1002/jha2.544
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.

Ferreri, Andrés J M / Angelillo, Piera / Erbella, Federico / Cattaneo, Chiara / Verga, Luisa / Lleshi, Arben / Allione, Bernardino / Ponzoni, Maurilio / Facchetti, Fabio / Pagani, Chiara / Foppoli, Marco / Pecciarini, Lorenza / Sassone, Marianna / Steffanoni, Sara / Flospergher, Elena / Rossi, Giuseppe / Spina, Michele / Re, Alessandro

Blood advances

2022 Volume 6, Issue 22, Page(s) 5811–5820

Abstract: Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with Burkitt ... ...

Abstract	Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with Burkitt lymphoma ([BL] n = 46) or high-grade B-cell lymphoma ([HGBCL] single, double, or triple hit; n = 22) were treated with a dose-dense, short-term therapy termed "CARMEN regimen" at 5 Italian centers. Forty-six (68%) patients were HIV+. CARMEN included a 36-day induction with sequential, single weekly doses of cyclophosphamide, vincristine, rituximab, methotrexate, etoposide, and doxorubicin plus intrathecal chemotherapy, followed by high-dose-cytarabine-based consolidation. Patients who did not achieve complete remission (CR) after induction received BEAM (carmustina, etoposide, cytarabine, melfalan)-conditioned autologous stem cell transplantation (ASCT) after consolidation. Sixty-one (90%) patients completed induction, and 59 (87%) completed consolidation. Seventeen patients received ASCT. Grade 4 hematological toxicity was common but did not cause treatment discontinuation; grade 4 nonhematological toxicity was recorded in 11 (16%) patients, with grade 4 infections in 6 (9%). Six (9%) patients died of toxicity (sepsis in 4, COVID-19, acute respiratory distress syndrome). CR rate after the whole treatment was 73% (95% confidence interval [CI], 55% to 91%) for patients with HGBCL and 78% (95% CI, 66% to 90%) for patients with BL. At a median follow-up of 65 (interquartile range, 40-109) months, 48 patients remain event free, with a 5-year progression-free survival of 63% (95% CI, 58% to 68%) for HGBCL and 72% (95% CI, 71% to 73%) for BL, with a 5-year overall survival (OS) of 63% (95% CI, 58% to 68%) and 76% (95% CI, 75% to 77%), respectively. HIV seropositivity did not have a detrimental effect on outcome. This retrospective study shows that CARMEN is a safe and active regimen both in HIV-negative and -positive patients with MYC-rearranged lymphomas. Encouraging survival figures, attained with a single dose of doxorubicin and cyclophosphamide, deserve further investigation in HGBCL and other aggressive lymphomas.
MeSH term(s)	Humans ; Rituximab/therapeutic use ; Vincristine/adverse effects ; Etoposide/adverse effects ; Hematopoietic Stem Cell Transplantation ; Retrospective Studies ; In Situ Hybridization, Fluorescence ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation, Autologous ; COVID-19 ; Cyclophosphamide/adverse effects ; Prednisone/therapeutic use ; Cytarabine/adverse effects ; Burkitt Lymphoma/drug therapy ; Burkitt Lymphoma/genetics ; Doxorubicin/adverse effects ; Lymphoma, B-Cell/drug therapy ; Lymphoma/drug therapy ; HIV Infections/drug therapy
Chemical Substances	Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Etoposide (6PLQ3CP4P3) ; Antibodies, Monoclonal, Murine-Derived ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT) ; Cytarabine (04079A1RDZ) ; Doxorubicin (80168379AG)
Language	English
Publishing date	2022-05-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2022007475
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.

Bossi, Elisa / Aroldi, Andrea / Brioschi, Filippo A / Steidl, Carolina / Baretta, Silvia / Renso, Rossella / Verga, Luisa / Fontana, Diletta / Sharma, Geeta G / Mologni, Luca / Mussolin, Lara / Piazza, Rocco / Gambacorti-Passerini, Carlo

American journal of hematology

2020 Volume 95, Issue 12, Page(s) E319–E321

MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Crizotinib/administration & dosage ; Disease-Free Survival ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; Lymphoma, Large-Cell, Anaplastic/drug therapy ; Lymphoma, Large-Cell, Anaplastic/enzymology ; Lymphoma, Large-Cell, Anaplastic/mortality ; Male ; Middle Aged ; Protein Kinase Inhibitors/administration & dosage ; Recurrence ; Survival Rate
Chemical Substances	Protein Kinase Inhibitors ; Crizotinib (53AH36668S) ; ALK protein, human (EC 2.7.10.1) ; Anaplastic Lymphoma Kinase (EC 2.7.10.1)
Language	English
Publishing date	2020-09-03
Publishing country	United States
Document type	Clinical Trial, Phase II ; Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.25967
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito